Australia fulfils HIV/AIDS funding commitments to Asia-Pacific:
This article was originally published in Clinica
Executive Summary
Australia has committed almost Aus$400m (US$325m) to its Asia-Pacific HIV/AIDS programmes. Last year, Aus$600m was allocated, completing Australia's original Aus$1bn pledge to this region. This year, Indonesia will receive Aus$86m to improve its HIV/AIDS services, as part of a partnership between the two countries. The funds are to be distributed by 2010, through Australia's foreign aid agency AusAID. Special focus will be on Papua New Guinea, where there has been a significant increase in the incidence of HIV/AIDS during the past 10 years (see Clinica No 1246, p 10).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.